<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00093652</url>
  </required_header>
  <id_info>
    <org_study_id>I 04603</org_study_id>
    <secondary_id>RPCI-I-04603</secondary_id>
    <secondary_id>ZENECA-IRUSIRES0303</secondary_id>
    <nct_id>NCT00093652</nct_id>
  </id_info>
  <brief_title>Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer</brief_title>
  <official_title>ZD1839 (IRESSA®) With Oxaliplatin and Radiotherapy for Esophageal Carcinoma. A Phase I/II Study With Biologic Correlates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Gefitinib may stop the growth of tumor&#xD;
      cells by blocking the enzymes necessary for their growth. Radiation therapy uses high-energy&#xD;
      x-rays to damage tumor cells. Combining oxaliplatin and gefitinib with radiation therapy may&#xD;
      kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of oxaliplatin when&#xD;
      given together with gefitinib and radiation therapy and to see how well they work in treating&#xD;
      patients with locally advanced or metastatic esophageal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of oxaliplatin when administered with gefitinib and&#xD;
           radiotherapy in patients with locally advanced or metastatic adenocarcinoma or squamous&#xD;
           cell carcinoma of the esophagus or gastroesophageal junction. (Phase I)&#xD;
&#xD;
        -  Determine the response rate in patients treated with this regimen. (Phase II)&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine time to tumor progression and median survival in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine quality of life in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a phase I, open-label, dose-escalation study of oxaliplatin followed by a&#xD;
      phase II study.&#xD;
&#xD;
        -  Phase I: Patients receive oxaliplatin IV over 2 hours on days 1, 15, and 29. Beginning&#xD;
           on day 1, patients undergo radiotherapy once daily, 5 days a week, for 5.5 weeks.&#xD;
           Patients also receive oral gefitinib once daily on days 1-365. Treatment continues in&#xD;
           the absence of disease progression or unacceptable toxicity Approximately 3-6 weeks&#xD;
           after the completion of chemoradiotherapy, patients are evaluated. Some patients undergo&#xD;
           surgical resection* and possibly receive a second course of oxaliplatin (IV over 2 hours&#xD;
           on days 1, 15, and 29) 4-8 weeks after surgery. If surgery is not indicated, some&#xD;
           patients may receive an additional course of oxaliplatin.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of oxaliplatin until the maximum tolerated&#xD;
      dose is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6&#xD;
      patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive oxaliplatin, gefitinib, and radiotherapy as in phase I at the&#xD;
           MTD. Some patients then either undergo surgical resection* and/or begin a second course&#xD;
           of oxaliplatin as in phase I.&#xD;
&#xD;
      NOTE: *Oral gefitinib is discontinued ≥ 7 days before surgery and is restarted when the&#xD;
      patient has recovered.&#xD;
&#xD;
      Quality of life is assessed at baseline, 5-6 weeks, and then every 2-3 months for 1 year.&#xD;
&#xD;
      Patients are followed every 2-3 months for 1 year.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 15-45 patients (3-12 for phase I and 12-33 for phase II)&#xD;
      will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2003</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (phase I)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response (phase II)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunohistochemistry</measure>
  </secondary_outcome>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus or&#xD;
             gastroesophageal (GE) junction&#xD;
&#xD;
               -  Locally advanced or metastatic disease by clinical staging, including&#xD;
                  esophagogastroduodenoscopy and esophageal ultrasound&#xD;
&#xD;
                    -  Stage T2, N0 disease and beyond&#xD;
&#xD;
               -  Bulk of tumor must be in the esophagus of patients with GE junction tumor&#xD;
&#xD;
                    -  Bronchoscopy is required if primary esophageal tumor is &lt; 26 cm from the&#xD;
                       incisors&#xD;
&#xD;
          -  No brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  WBC ≥ 3,000/mm^3&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  ALT and AST ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No clinically active interstitial lung disease&#xD;
&#xD;
               -  Patients with chronic stable asymptomatic radiographic changes are eligible&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective double-method (including barrier) contraception&#xD;
             during and for 3 months after study participation&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade II&#xD;
&#xD;
          -  No severe hypersensitivity to gefitinib or any of its excipients&#xD;
&#xD;
          -  No history of allergy to platinum-based compounds or antiemetics administered with&#xD;
             protocol-directed chemotherapy&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No other significant clinical disorder or laboratory finding that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent colony-stimulating factors during course 1 of study therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent steroid therapy allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior non-approved or investigational drugs&#xD;
&#xD;
          -  No concurrent administration of any of the following:&#xD;
&#xD;
               -  Phenytoin&#xD;
&#xD;
               -  Carbamazepine&#xD;
&#xD;
               -  Rifampin&#xD;
&#xD;
               -  Barbiturates&#xD;
&#xD;
               -  Highly-active antiretroviral therapy (HAART)&#xD;
&#xD;
               -  Hypericum perforatum (St. John's wort)&#xD;
&#xD;
          -  No other concurrent investigational agents or therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Milind Javle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Javle M, Pande A, Iyer R, Yang G, LeVea C, Wilding G, Black J, Nava H, Nwogu C. Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response. Am J Clin Oncol. 2008 Aug;31(4):329-34. doi: 10.1097/COC.0b013e318161dc04.</citation>
    <PMID>18845990</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 6, 2004</study_first_submitted>
  <study_first_submitted_qc>October 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2004</study_first_posted>
  <last_update_submitted>October 5, 2015</last_update_submitted>
  <last_update_submitted_qc>October 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2015</last_update_posted>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

